Interventional × Neuroendocrine Tumors × Gastrointestinal × Clear all
NCT02568267 2026-03-06

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 1 FDA
NCT04907643 2026-02-20

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Cedars-Sinai Medical Center

Phase NA Recruiting
360 enrolled
NCT04459273 2026-02-05

FAPI PET RDRC

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
26 enrolled
NCT06943521 2025-12-11

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Tanabe Pharma America, Inc.

Phase 1/2 Recruiting
27 enrolled
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 5 FDA
NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

Phase 1 Recruiting
30 enrolled
NCT03093116 2025-07-10

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 5 FDA
NCT06638931 2025-05-28

ANTARES

Instituto do Cancer do Estado de São Paulo

Phase 2 Active not recruiting
28 enrolled
NCT04644315 2023-08-07

ALpha-T

Hoffmann-La Roche

Phase 2 Terminated
1 enrolled 5 charts